<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124506">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02075073</url>
  </required_header>
  <id_info>
    <org_study_id>SB3-G11-NHV</org_study_id>
    <secondary_id>2013-004112-21</secondary_id>
    <nct_id>NCT02075073</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects</brief_title>
  <official_title>A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Trastuzumab (SB3, EU Sourced Herceptin® and US Sourced Herceptin®) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics, safety, tolerability and
      immunogenicity of SB3 and Herceptin® (EU sourced Herceptin® and US sourced Herceptin®) in
      healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>57 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>57 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)</measure>
    <time_frame>57 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>57 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SB3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB3, single dose of 6 mg/kg via intravenous infusion (study drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU sourced Herceptin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US sourced Herceptin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB3</intervention_name>
    <arm_group_label>SB3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU sourced Herceptin®</intervention_name>
    <arm_group_label>EU sourced Herceptin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US sourced Herceptin®</intervention_name>
    <arm_group_label>US sourced Herceptin®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects

          -  Have a body weight between 60.0 and 94.9 kg and a body mass index between 18.0 and
             29.9 kg/m², inclusive.

        Exclusion Criteria:

          -  history of and/or current clinically significant gastrointestinal, renal, hepatic,
             cardiovascular, haematological (including pancytopenia, aplastic anaemia or blood
             dyscrasia), pulmonary, neurologic, metabolic (including known diabetes mellitus),
             psychiatric or significant allergic disease excluding mild asymptomatic allergies.

          -  history of and/or current cardiac disease

          -  previously received any monoclonal antibody or fusion protein.

          -  history of cancer including lymphoma, leukaemia and skin cancer.

          -  Have received live vaccine(s) within 30 days prior to Screening or who will require a
             vaccine(s) between Screening and the End of Study visit.

          -  intake medication with a half-life &gt; 24 h within 1 month or 10 half-lives of the
             medication prior to the administration of investigational product.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saumsung Bioepis</last_name>
    <role>Study Director</role>
    <affiliation>Samsung Bioepis Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>February 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
